Hemopexin, salubrinal, aurothioglucose, and nitrite find uses in treating pulmonary injury from several causes, alone and in combination. Methods of treatment, methods of prevention, and pharmaceutical compositions are provided with those components.

Hemopexin, salubrinal, aurothioglucose, and nitrite find uses in treating pulmonary injury from several causes, alone and in combination. Methods of treatment, methods of prevention, and pharmaceutical compositions are provided with those components.

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt; wherein L is a substituted or non-substituted aromatic ligand; Z is a halogen or coordinating ligand; M is a group 8 or group 9 transition metal selected from; Fe, Ru, Os, Co, Rh and Os; A and B are independently selected from a substituted or non-substituted indole or pyridine, may be the same or different and coordinate to the transition metal M through the nitrogen atom of the indole or pyridine. The compounds have been shown to have use against antibiotic-resistant bacteria. A further aspect of the invention is directed towards treating or preventing bacterial infections.

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt; wherein L is a substituted or non-substituted aromatic ligand; Z is a halogen or coordinating ligand; M is a group 8 or group 9 transition metal selected from; Fe, Ru, Os, Co, Rh and Os; A and B are independently selected from a substituted or non-substituted indole or pyridine, may be the same or different and coordinate to the transition metal M through the nitrogen atom of the indole or pyridine. The compounds have been shown to have use against antibiotic-resistant bacteria. A further aspect of the invention is directed towards treating or preventing bacterial infections.

Injectable iron compositions comprising iron, a carbohydrate, a stabilizing agent and water are provided. These iron compositions can be prepared by mixing iron with a carbohydrate and water to form a mixture and adding a stabilizing agent to the mixture to form the stable injectable iron composition. These compositions can be considered “ready-to-use” and can treat a variety of diseases, disorders, or conditions characterized by iron deficiency or dysfunctional iron metabolism, for example, anemia.

Injectable iron compositions comprising iron, a carbohydrate, a stabilizing agent and water are provided. These iron compositions can be prepared by mixing iron with a carbohydrate and water to form a mixture and adding a stabilizing agent to the mixture to form the stable injectable iron composition. These compositions can be considered “ready-to-use” and can treat a variety of diseases, disorders, or conditions characterized by iron deficiency or dysfunctional iron metabolism, for example, anemia.

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease and are immune stimulatory, promote zinc uptake, disable endosomal reactions and synergise anti-viral action of protease inhibitors. The compounds are useful for the treatment of bacterial, viral and mixed pneumonias.

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease and are immune stimulatory, promote zinc uptake, disable endosomal reactions and synergise anti-viral action of protease inhibitors. The compounds are useful for the treatment of bacterial, viral and mixed pneumonias.

Provided is an L-glucose derivative represented by General Formula (1) below:

##STR00001## wherein X.sup.1 represents a —SAuR.sup.1 group, and X.sup.2, X.sup.3, X.sup.4 and X.sup.5 each independently represent an —OR.sup.2 group, an —NH.sup.2 group, or a fluorine atom; and R.sup.1 represents a ligand and R.sup.2 represents a hydrogen atom or an organic group.

Compositions comprising metal entities in combination with an activating agent, or pharmaceutically acceptable salts thereof are disclosed. Certain compositions are active as antibacterial, antiviral, antifungal, anti-protozoal, and/or anti-worm agents. The disclosure provides pharmaceutical compositions containing the compositions. Methods of using the composition to treat bacterial infections are disclosed.